ArticleJournal of immunology (Baltimore, Md. : 1950)2011
Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humans.
Article in Journal of immunology (Baltimore, Md. : 1950), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 43 citations in OpenAlex.
- Terminal complement complexes with or without C9 potentiate antimicrobial activity againstmBio · 2025Article
- Ticks' tricks: immunomodulatory effects of ixodid tick saliva at the cutaneous tick-host interface.Frontiers in immunology · 2025Review
- Reconstitution of the alternative pathway of the complement system enables rapid delineation of the mechanism of action of novel inhibitors.The Journal of biological chemistry · 2024Article
- Immunomodulatory Proteins in Tick Saliva From a Structural Perspective.Frontiers in cellular and infection microbiology · 2021Review
- Development of a Sensitive Assay to Screen NanoparticlesACS biomaterials science & engineering · 2020Article
- A soft tick Ornithodoros moubata salivary protein OmCI is a potent inhibitor to prevent avian complement activation.Ticks and tick-borne diseases · 2020Article
- Tick Salivary Compounds for Targeted Immunomodulatory Therapy.Frontiers in immunology · 2020Review
- Complement Component C5 and TLR Molecule CD14 Mediate Heme-Induced Thromboinflammation in Human Blood.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease.JCI insight · 2019Article
- Deciphering Biological Processes at the Tick-Host Interface Opens New Strategies for Treatment of Human Diseases.Frontiers in physiology · 2019Review
- Complement factor 5 blockade reduces porcine myocardial infarction size and improves immediate cardiac function.Basic research in cardiology · 2017Article
- Complement in Non-Antibody-Mediated Kidney Diseases.Frontiers in medicine · 2017Review
- Substrate prediction of Ixodes ricinus salivary lipocalins differentially expressed during Borrelia afzelii infection.Scientific reports · 2016Article
- Stratification of responders towards eculizumab using a structural epitope mapping strategy.Scientific reports · 2016Article
- Structural basis for therapeutic inhibition of complement C5.Nature structural & molecular biology · 2016Article
- Effect of O. porcinus Tick Salivary Gland Extract on the African Swine Fever Virus Infection in Domestic Pig.PloS one · 2016Article
- Applying complement therapeutics to rare diseases.Clinical immunology (Orlando, Fla.) · 2015Review
- Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape.Expert review of hematology · 2014Review
- Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Post challenge inhibition of C3 and CD14 attenuates Escherichia coli-induced inflammation in human whole blood.Innate immunity · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
Experimental evidence suggests that C inhibition and more particularly combined inhibition of C and the TLR coreceptor CD14 may be of therapeutic benefit in sepsis and other inflammatory conditions. A barrier to the testing and further development of many inhibitors is that their activity is species specific. Pig is a relevant species for experimental models of human disease, and this study undertakes a comprehensive comparison of the inhibitory efficacy of the C5 inhibitor Ornithodoros moubata C inhibitor (OmCI) in human and porcine whole blood ex vivo models of Escherichia coli-induced sepsis. The effect of OmCI on complement activity in pigs undergoing E. coli sepsis was also examined. Porcine and human serum, and whole blood anticoagulated with lepirudin, was incubated with E. coli and the effect of OmCI investigated. The ex vivo results were virtually identical in pig and human. OmCI completely ablated the activity of all three C pathways at 0.64 μM. E. coli-induced C activation and expression of CD11b (wCD11R3 in the pig), was abolished ex vivo at 0.32 μM OmCI. Combining anti-CD14 and OmCI reduced the formation of IL-8 and TNF-α more potently than the single inhibitors. OmCI also efficiently bound E. coli-induced leukotriene B(4) in pig and human plasma. In support of our ex vivo findings, in vivo the activity of all C pathways was inhibited at 0.6 mg OmCI/kg pig. In conclusion, OmCI efficiently inhibited pig and human C activation, has accompanying anti-inflammatory effects and is a promising candidate inhibitor for further in vivo studies of sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.